• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

How an Advocate Unites Voices to Guide MPN Research Decisions

by MM360 Staff | Apr 28, 2025 | Uncategorized

Source: CureToday articles Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population. Read More

Treatment With HT-KIT Shows Early Preclinical Activity in GIST Models

by MM360 Staff | Apr 27, 2025 | Uncategorized

Source: CureToday articles HT-KIT, a novel targeted therapy for GIST, demonstrated the ability to reduce tumor burden in humanized mouse models and induce tumor cell death. Read More

Healer, Mentor and Leader

by MM360 Staff | Apr 27, 2025 | Uncategorized

Source: CureToday articles Reflecting upon my relationship with Jill over the past 25 years, I am in awe of all she has accomplished. Read More

FDA OKs Investigational New Drug Application for VS-7375 in Solid Tumors

by MM360 Staff | Apr 26, 2025 | Uncategorized

Source: CureToday articles Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be presented at ASCO 2025. Read More

Crafting an Individual Treatment Plan for Patients With Prostate Cancer

by MM360 Staff | Apr 26, 2025 | Uncategorized

Source: CureToday articles Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer. Read More

Commitment to Patients Is Driven by a Lasting Promise

by MM360 Staff | Apr 25, 2025 | Uncategorized

Source: CureToday articles Mikela Pettigrew, B.S.N., RN, OCN,, exemplifies extraordinary compassion and dedication. Every day, she fulfills a promise she made as a young caregiver. Read More
« Older Entries
Next Entries »

Recent Content

  • (no title)
  • New center promotes advocacy for gynecological cancer patients
  • FDA clears Thermo Fisher EXTENT system for myeloma diagnosis
  • Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma
  • TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
  • (no title)
  • (no title)
  • New ‘powerful’ lab test will help researchers explore blood cancer
  • Assessing the correlation between patient and family reported outcome measures and multiple myeloma clinical parameters
  • Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT